Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11089881 | PMC |
| http://dx.doi.org/10.1177/19322968241228538 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Access to High-Resolution Anoscopy and Colorectal Surgery Support Identified as Important Facilitators to Successful Veterans Affairs Anal Cancer Screening Programs.
Dis Colon Rectum
October 2024
Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Background: Anal cancer disproportionately affects people living with HIV. The Department of Veterans Affairs is the largest single provider of healthcare to people living with HIV in the U.S.
View Article and Find Full Text PDFGermline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline.
J Clin Oncol
January 2025
Jefferson Einstein Medical Center, Sidney Kimmel Cancer Center of Thomas Jefferson University, Philadelphia, PA.
Purpose: To evaluate evidence on germline and somatic genomic testing for patients with metastatic prostate cancer and provide recommendations.
Methods: A systematic review by a multidisciplinary panel with patient representation was conducted. The PubMed database was searched from January 2018 to May 2024.
The Effect of Denosumab on Pain and Radiological Improvement in Giant Cell Tumours of the Spine in the Acute Setting.
Global Spine J
January 2025
Department of Spinal Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Study Design: Retrospective Cohort Study.
Objectives: The current recommended treatment for Giant Cell Tumour (GCT) of the spine is en bloc excision. Denosumab is a monoclonal antibody reducing osteoclast activity that shows promising results when used as a neo - adjuvant treatment.
Cellular therapy for the peripheral arterial disease treatment: Protocol for a systematic review and meta-analysis.
PLoS One
January 2025
Department of Nursing and Podiatry, University of Malaga, Malaga, Spain.
Cellular therapy is a promising treatment option for Peripheral Arterial Disease (PAD). Different cell types can be used to regenerate and repair tissues affected by PAD. Many studies have proposed the use of stem cells, such as mesenchymal stem cells, or even mononuclear cells isolated from peripheral blood or bone marrow, to treat PAD.
View Article and Find Full Text PDFPitfalls and perils from FDA-approved germ-line cancer predisposition tests.
Oncotarget
December 2024
The FDA approval on September 29, 2023, for "class III " blood tests to assess hereditary cancer risk make widely available tests that may be obtained through a Direct to Consumer (DTC) path. There is concern that germ-line predisposition tests may not be reimbursed by insurance adding financial burdens to individuals and families. It is generally agreed in the fields on oncology and genetics that germ-line testing for disease susceptibility including cancer is best performed under care of a healthcare provider with genetic counseling.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!